XML 39 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Acquisitions (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jul. 05, 2016
Sep. 30, 2015
Apr. 30, 2017
Apr. 30, 2016
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Asset acquisition of MiaMed, Inc.                
Common stock, par value (in dollars per share)         $ 0.01   $ 0.01  
Contingent consideration payable         $ 274,300   $ 269,722  
Contingent consideration payable, current portion         56,101   56,101  
Changes in fair value of contingent consideration payable         4,578 $ 3,152    
IPR&D                
Asset acquisition of MiaMed, Inc.                
Intangible assets-IPR&D         486,700   $ 486,700  
Scioderm                
Asset acquisition of MiaMed, Inc.                
Initial amount to Effective Time Holders   $ 223,900            
Initial amount cash payment excluding Series B Preferred   141,100            
Initial amount paid in shares of Common Stock   $ 82,800            
Priority review voucher transfer years   1 year            
Payment to be made if Priority Review Voucher is obtained and used   $ 100,000            
Contingent consideration payable   259,000     $ 264,000      
Enrollment rate (as a percent)         100.00%      
Milestone payment     $ 10,000          
Contingent consideration payable, current portion         $ 56,100      
Scioderm | Changes in fair value of contingent consideration payable                
Asset acquisition of MiaMed, Inc.                
Changes in fair value of contingent consideration payable         4,000      
Scioderm | IPR&D                
Asset acquisition of MiaMed, Inc.                
Intangible assets-IPR&D               $ 463,700
Scioderm | Maximum                
Asset acquisition of MiaMed, Inc.                
Priority Review Voucher sale proceeds shared   $ 100,000            
Priority Review Voucher sale proceeds shared (as a percent)   50.00%            
Scioderm | Scioderm | Series B Preferred Stock                
Asset acquisition of MiaMed, Inc.                
Consideration paid in common stock   5,900,000            
MiaMed Inc                
Asset acquisition of MiaMed, Inc.                
Asset acquisition, total consideration, stock and cash $ 6,500              
Asset acquisition, cash consideration paid 1,800              
Asset acquisition, potential aggregate deal value 89,500              
Charges to research expense for stock issued in asset acquisition $ 6,500              
MiaMed Inc | Amicus | Common Stock                
Asset acquisition of MiaMed, Inc.                
Asset acquisition, consideration paid in common stock 825,603              
Common stock, par value (in dollars per share) $ 0.01              
Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum                
Asset acquisition of MiaMed, Inc.                
Contingent consideration payable upon achievement of milestones $ 83,000              
Clinical and Regulatory Approval milestones | Scioderm                
Asset acquisition of MiaMed, Inc.                
Contingent consideration payable         237,800      
Clinical and Regulatory Approval milestones | Scioderm | Minimum                
Asset acquisition of MiaMed, Inc.                
Discount rate (as a percent)   0.40%            
Clinical and Regulatory Approval milestones | Scioderm | Maximum                
Asset acquisition of MiaMed, Inc.                
Upfront cash payments   $ 361,000   $ 361,000        
Discount rate (as a percent)   1.10%            
Revenue-based milestones | Scioderm                
Asset acquisition of MiaMed, Inc.                
Upfront equity payments   $ 257,000            
Contingent consideration payable         26,200      
Revenue-based milestones | Scioderm | Minimum                
Asset acquisition of MiaMed, Inc.                
Discount rate (as a percent)   1.00%            
Revenue-based milestones | Scioderm | Maximum                
Asset acquisition of MiaMed, Inc.                
Upfront equity payments         $ 257,000      
Discount rate (as a percent)   2.20%            
Clinical milestone | Scioderm | Maximum                
Asset acquisition of MiaMed, Inc.                
Upfront cash payments       81,000        
Regulatory Approval milestone | Scioderm | Maximum                
Asset acquisition of MiaMed, Inc.                
Upfront cash payments       $ 280,000